CL2017001422A1 - Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas - Google Patents

Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas

Info

Publication number
CL2017001422A1
CL2017001422A1 CL2017001422A CL2017001422A CL2017001422A1 CL 2017001422 A1 CL2017001422 A1 CL 2017001422A1 CL 2017001422 A CL2017001422 A CL 2017001422A CL 2017001422 A CL2017001422 A CL 2017001422A CL 2017001422 A1 CL2017001422 A1 CL 2017001422A1
Authority
CL
Chile
Prior art keywords
inhibitors
pyrazolo
janus kinases
substituted pyrazines
jak
Prior art date
Application number
CL2017001422A
Other languages
English (en)
Spanish (es)
Inventor
Laurence E Burguess
Ellen Laird
Ronald Jay Hinklin
Shelley Allen
Erik James Hicken
Mark Laurencie Boys
Mark J Chicarelli
Jay Bradford Fell
John P Fischer
John Gaudino
Christopher F Kraser
John E Robinson
Tony P Tang
Robert Andrew Rieger
Jed Pheneger
Yoshitaka Satoh
Katerina Lefheris
Raj K Raheja
Brydon L Bennett
Original Assignee
Celgene Corp
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp, Array Biopharma Inc filed Critical Celgene Corp
Publication of CL2017001422A1 publication Critical patent/CL2017001422A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
CL2017001422A 2014-12-05 2017-06-05 Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas CL2017001422A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462088068P 2014-12-05 2014-12-05

Publications (1)

Publication Number Publication Date
CL2017001422A1 true CL2017001422A1 (es) 2018-01-05

Family

ID=55069089

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001422A CL2017001422A1 (es) 2014-12-05 2017-06-05 Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas

Country Status (29)

Country Link
US (3) US10189845B2 (https=)
EP (2) EP3878451A1 (https=)
JP (2) JP6641373B2 (https=)
KR (1) KR20170090476A (https=)
CN (1) CN107278203B (https=)
AU (1) AU2015357585B2 (https=)
BR (1) BR112017011798A2 (https=)
CA (1) CA2969709A1 (https=)
CL (1) CL2017001422A1 (https=)
CO (1) CO2017006674A2 (https=)
CR (1) CR20170309A (https=)
DK (1) DK3227297T3 (https=)
ES (1) ES2865483T3 (https=)
HR (1) HRP20210501T1 (https=)
HU (1) HUE054371T2 (https=)
IL (1) IL252656A0 (https=)
MX (1) MX386316B (https=)
MY (1) MY191016A (https=)
PH (1) PH12017501032A1 (https=)
PL (1) PL3227297T3 (https=)
PT (1) PT3227297T (https=)
RS (1) RS61693B1 (https=)
RU (2) RU2742938C2 (https=)
SG (1) SG11201704542SA (https=)
SI (1) SI3227297T1 (https=)
TW (1) TWI725004B (https=)
UA (1) UA120065C2 (https=)
WO (1) WO2016090285A1 (https=)
ZA (1) ZA201704494B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE054371T2 (hu) 2014-12-05 2021-09-28 Array Biopharma Inc 4,6-szubsztituált pirazolo[l,5-A]pirazinok mint janus kináz inhibitorok
CR20180372A (es) 2016-02-24 2018-09-19 Pfizer Derivados de pirazolo [1,5-a] pirazin-4-ilo
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
MD3472153T2 (ro) 2016-06-16 2022-03-31 Denali Therapeutics Inc Pirimidin-2-ilamino-1H-pirazoli în calitate de inhibitori L RRK2 pentru utilizare în tratamentul tulburărilor neurodegenerative
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018217946A1 (en) * 2017-05-24 2018-11-29 Denali Therapeutics Inc. Compounds, compositions and methods
WO2019034973A1 (en) 2017-08-14 2019-02-21 Pfizer Inc. PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
CN113924301B (zh) * 2019-04-12 2024-08-16 北京普祺医药科技股份有限公司 一种吡唑并吡嗪衍生的化合物、药物组合物以及其用途
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
CN113150012B (zh) * 2020-01-22 2023-03-24 浙江海正药业股份有限公司 吡唑并[1,5-a]吡嗪类衍生物及其制备方法和用途
MX2022012135A (es) 2020-04-04 2023-01-18 Pfizer Métodos para tratar la enfermedad de coronavirus de 2019.
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
AU2022387652B2 (en) * 2021-11-12 2025-10-16 Cms Research & Development Pte. Ltd. Pyrazolo fused ring compound and use thereof
CN121568938A (zh) * 2023-05-12 2026-02-24 海南德镁医药科技有限责任公司 一种吡唑并吡嗪类化合物及其晶型的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313129B1 (en) 1998-08-21 2001-11-06 Hughes Institute Therapeutic compounds
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
SG181857A1 (en) * 2009-12-23 2012-07-30 Takeda Pharmaceutical Fused heteroaromatic pyrrolidinones as syk inhibitors
EP2526102B1 (en) * 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
US20110241987A1 (en) * 2010-04-01 2011-10-06 Smart Technologies Ulc Interactive input system and information input method therefor
KR20130094710A (ko) 2010-04-14 2013-08-26 어레이 바이오파마 인크. Jak 키나아제의 억제제로서 5,7-치환된-이미다조[1,2-c]피리미딘
US20140228349A1 (en) * 2011-10-12 2014-08-14 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
MX351149B (es) * 2012-03-28 2017-10-04 Merck Patent Gmbh Derivados biciclicos de pirazinona.
HUE054371T2 (hu) 2014-12-05 2021-09-28 Array Biopharma Inc 4,6-szubsztituált pirazolo[l,5-A]pirazinok mint janus kináz inhibitorok

Also Published As

Publication number Publication date
ES2865483T3 (es) 2021-10-15
US20190177328A1 (en) 2019-06-13
RU2021102805A (ru) 2021-02-12
SG11201704542SA (en) 2017-07-28
US10189845B2 (en) 2019-01-29
US20170362240A1 (en) 2017-12-21
WO2016090285A1 (en) 2016-06-09
TWI725004B (zh) 2021-04-21
JP6641373B2 (ja) 2020-02-05
KR20170090476A (ko) 2017-08-07
MY191016A (en) 2022-05-28
PT3227297T (pt) 2021-04-09
AU2015357585B2 (en) 2020-07-02
CR20170309A (es) 2018-02-02
JP2018507167A (ja) 2018-03-15
TW201632523A (zh) 2016-09-16
RS61693B1 (sr) 2021-05-31
PH12017501032A1 (en) 2017-11-27
US20200291039A1 (en) 2020-09-17
AU2015357585A1 (en) 2017-07-13
CA2969709A1 (en) 2016-06-09
HUE054371T2 (hu) 2021-09-28
IL252656A0 (en) 2017-07-31
UA120065C2 (uk) 2019-09-25
MX2017007284A (es) 2017-08-25
US10730880B2 (en) 2020-08-04
RU2017123387A3 (https=) 2019-06-03
CN107278203A (zh) 2017-10-20
PL3227297T3 (pl) 2021-10-25
BR112017011798A2 (pt) 2017-12-26
JP2020055859A (ja) 2020-04-09
EP3878451A1 (en) 2021-09-15
US11028093B2 (en) 2021-06-08
EP3227297A1 (en) 2017-10-11
DK3227297T3 (da) 2021-04-06
RU2742938C2 (ru) 2021-02-11
SI3227297T1 (sl) 2021-04-30
ZA201704494B (en) 2022-03-30
MX386316B (es) 2025-03-18
EP3227297B1 (en) 2021-01-20
CN107278203B (zh) 2020-05-19
RU2017123387A (ru) 2019-01-11
CO2017006674A2 (es) 2017-10-20
HRP20210501T1 (hr) 2021-05-14

Similar Documents

Publication Publication Date Title
CL2017001422A1 (es) Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas
CL2018003060A1 (es) Compuestos de pirimidina como inhibidores de la quinasa jak.
UY34388A (es) "5,7-IMIDAZO[1,2-c]PIRIMIDINAS SUSTITUIDAS"
CO6630187A2 (es) 5.7-sustituido -imidazol[1.2-c]pirimidinas como inhibidores de cinasas jak
MX2020012520A (es) Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia.
SV2018005655A (es) "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer"
CU20200070A7 (es) Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de quinasa dependientes de ciclina
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
MX2020011558A (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
MX2019005306A (es) Compuestos mono y espirociclicos que continen ciclobutano y azetidina como inhibidores de la integrina alfa v.
MX376465B (es) Compuestos de pirazolo[1,5-4]piridina sustituidos como inhibidores de la quinasa ret.
CR20150633A (es) Derivados del bipirazol como inhibidores jak
CO2018011064A2 (es) Inhibidores de bromodominios
CO2017003833A2 (es) Pirimidinonas como inhibidores del factor xia
CL2018001146A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
MX378957B (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
MX2019001096A (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
PH12016502252A1 (en) Addition salts of (s)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrile
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
SV2018005680A (es) Compuestos de imidazo [4,5-c] quinolin- 2-ona y su uso en el tratamiento del cancer
MX2018004664A (es) Antagonistas de ep4.
CO2019002171A2 (es) Compuestos 8-(azetidín-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de utilización de los mismos.
EA201650003A1 (ru) Соединённые циклоалкилом дигетероциклические производные